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Abstract
Background: The impact of comorbidity on the risk of revision in patients undergoing Total Knee arthroplasty
(TKA) and Total Hip Arthroplasty (THA) is not currently well known. The aim of this study was to analyze the impact
of comorbidity on the risk of revision in TKA and THA.
Methods: Patients recorded in the Catalan Arthroplasty Register (RACat) between 01/01/2005 and 31/12/2016
undergoing TKA (n = 49,701) and THA (n = 17,923) caused by osteoarthritis were included. As main explanatory factors,
comorbidity burden was assessed by the Elixhauser index, categorized, and specific comorbidities from the index were
taken into account. Descriptive analyses for comorbidity burden and specific conditions were done. Additionally,
incidence at 1 and 5 years’ follow-up was calculated, and adjusted Competing Risks models were fitted.
Results: A higher incidence of revision was observed when the number of comorbidities was high, both at 1 and 5
years for THA, but only at 1 year for TKA. Of the specific conditions, only obesity was related to the incidence of
revision at 1 year in both joints, and at 5 years in TKA. The risk of revision was related to deficiency anemia and liver
diseases in TKA, while in THA, it was related to peripheral vascular disorders, metastatic cancer and psychoses.
Conclusions: Different conditions, depending on the joint, might be related to higher revision rates. This information could
be relevant for clinical decision-making, patient-specific information and improving the results of both TKA and THA.
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Background
Total knee and hip arthroplasties (TKA and THA) are safe,
successful, and cost-effective treatments for late-stage osteo-
arthritis in the knee and hip that offer pain relief, better func-
tion and improved quality of life to the patient [1–5]. These
procedures have increased worldwide in the last few decades
[2, 6] and are expected to rise due to the increase in life
expectancy and prevalence of osteoarthritis [7, 8]. Previous
research shows that certain physical and mental comorbidi-
ties that are particularly prevalent in the elderly population
could have a greater risk of complications (medical, surgical,
and wound) following TKA and THA [3, 9].
TKA and THA are common considerations for effect-
ive procedures for patients with advanced osteoarthritis
[7, 10]. Although using comorbidities to predict clinical
outcomes has increased substantially in the past 20 years
for patients undergoing TKA and THA [2, 6, 11, 12],
their relationship to the risk of revision is unclear. More-
over, most joint arthroplasty patients have a high
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prevalence of comorbidities, which can affect surgical
outcomes, and previous studies have identified risk fac-
tors associated with lower implant survival [13]. Revision
surgery is a more demanding procedure than a primary
total joint arthroplasty (TJA) and thus requires more ex-
tensive resources [14]. Furthermore, late revisions are
becoming more common for patients, given the finite
life of an implant, coupled with the increased use of
THA in younger patients [15].
Several indices are currently available to assess the risk
of different outcomes, such as prosthesis revision, mor-
tality and Patient Reported Outcome Measures
(PROMs), based on the presence of comorbidities for
patients undergoing TKA and THA. Despite this, there
is still no consensus on an optimal approach for risk ad-
justment [16], but the Charlson Comorbidity Index
(CCI) and the Elixhauser Comorbidity Index are the two
most commonly used [17]. The Elixhauser index, intro-
duced in 1998 [18], is a composite measurement to as-
sess the impact of comorbidity on various surgical
procedures [19]. The original version of this index in-
cluded 30 burdensome conditions [7, 17, 18], like hyper-
tension, obesity, weight loss, and psychiatric disorders,
[8, 15, 20, 21] that have proven to be particularly rele-
vant in TKA and THA, due to their relationship with
prosthesis revision. Given that the aforementioned co-
morbidities are excluded from the CCI [16], growing evi-
dence suggests that the Elixhauser method is preferable
for risk-adjustment in orthopedic surgery [19].
Previous research has identified patient factors like
age, sex, obesity, and hospital characteristics that may
increase the revision risk for TKA [22]. An in-depth un-
derstanding of how comorbidity might influence the in-
cidence of revision should take these risk factors into
account to ensure the most accurate estimates possible.
This information could be useful in guiding clinical
decision-making, and consequently might reduce the
burden of revision surgery. Therefore, the aims of this
study were: 1) to examine patient characteristics and co-
morbidity distribution in those undergoing TKA and
THA; and 2) to analyze the impact of the burden of co-
morbidity, and that of the specific comorbidities in the
Elixhauser index, on the risk of revision at 1 and 5 years
in patients undergoing TKA and THA.
Methods
Study design and population
A retrospective observational study based on data from
the Catalan Arthroplasty Register (RACat) and the Mini-
mum Basic Dataset at Hospital Discharge (MBD-HD)
was carried out. The RACat is a population-based hip
and knee arthroplasty register that has collected infor-
mation since January 2005 on those types of surgical
procedures and their related aspects not accounted for
in the MBD-HD (e.g. laterality of the arthroplasty, fix-
ation type or the bearing surface in THA). The RACat
includes 52 out of 55 public hospitals in Catalonia that
perform knee and hip arthroplasty surgery, with an over-
all completeness of about 90% for primary arthroplasties
and about 70% for revision procedures [23].
The MBD-HD is a mandatory, payment-related ad-
ministrative database that provides information about
different aspects of the patient and surgical procedures,
like the patient’s main diagnosis and up to 10 secondary
diagnoses based on ICD-9-CM codes, as well as patient
characteristics and the causes of primary and revision in-
terventions. This dataset is linked to the RACat dataset
through a patient identification number and other vari-
ables like the hospital admission, surgery and hospital
discharge dates. Additionally, given that the MBD-HD is
a payment-related dataset and all procedures performed
in public hospitals should be reported, it was used as a
standard to calculate the completeness of the RACat.
Study variables
For the present study, the first revision of the primary
TKA and THA was considered as the main outcome. A
revision arthroplasty was defined by the RACat as any
procedure involving removal, exchange or addition of
any implant component. Patient follow-up started 1
January 2005 and ended 1 January 2017.
Both comorbidity burden and the specific comorbidi-
ties at the time of the primary intervention were consid-
ered as main explanatory variables. The specific
conditions included in the Elixhauser index were evalu-
ated. The Elixhauser index is a composite measurement
of comorbidity based on the Clinical Modification of the
ninth version the International Classification of Diseases
(ICD-9-CM) codes [7, 18]. The index is made up of 30
categories, each corresponding to a group of specific
diagnoses, including the following: hypertension without
complications, diabetes without complications, obesity,
depression, chronic pulmonary disease, hypothyroidism,
deficiency anemia, renal failure, hypertension with com-
plications, valvular disease, rheumatoid arthritis /colla-
gen vascular disease, other neurological disorders, liver
disease, congestive heart failure, peripheral vascular dis-
orders, solid tumor, diabetes with complications, coagu-
lopathy, blood loss anemia, fluid and electrolyte
disorders, alcohol abuse, psychoses, paralysis, pulmonary
circulation disorders, lymphoma, peptic ulcer disease
(excluding bleeding), drug abuse, metastatic cancer,
weight loss and AIDS. The comorbidity burden was con-
sidered as the number of specific comorbidities that each
individual presented from the index at the time of the
primary intervention. Based on the distribution of the
number of comorbidities in the studied population, with
a strong positive asymmetry, comorbidity burden was
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considered a categorical variable using tertiles as cut-off
values. The following levels were considered: 0 comor-
bidities, 1 comorbidity and 2 or more comorbidities.
Additionally, each of the specific comorbidities compos-
ing the index was considered separately.
The following covariates were also taken into account:
sex (male and female); age in years (continuous); pros-
thesis fixation (cemented, when the stem and cup in
THA were cemented and the tibial and femoral compo-
nents in TKA; uncemented when none of the prosthesis
components were cemented; hybrid when the stem in
THA was cemented but not the cup, and the tibial but
not the femoral component in TKA; and inverse hybrid
when the cup but not the stem was cemented in THA
and the femoral but not the tibial component was
cemented in TKA); year of intervention (categorized as
2005–2008, 2009–2011, 2012–2014 and 2015–2017) and
type of hospital, according to the range of services of-
fered in the hospital itself, irrespective of the patient’s
territorial assignment (high technology, reference, re-
gional and other type or not specified) [24].
Statistical analysis
Descriptive analyses of patient characteristics were done
as well as a description of the absolute and relative fre-
quencies of patients in the different levels of comorbidity
burden. A description of these frequencies in the specific
comorbidities included in the Elixhauser index was also
given.
Absolute and relative frequencies of revision in pa-
tients that presented comorbidity (for burden and for
the specific comorbidities) throughout the entire study
period (2005 to 2016) were obtained, and the incidence
of revision at 1 and 5 years was calculated, considering
patient death as the competing event of primary arthro-
plasty revision. Taking this into account, the incidence
of revision up to the 1st of January 2017 was estimated
by calculating t S (t-1) * h’ (t), where S (t-1) was the
Kaplan-Meier estimate of the overall survival function
and h’ (t) was the cause-specific hazard at time t. To as-
sess the relationship between comorbidity and risk of re-
vision, adjusted Fine and Gray Competing Risk
regression models were fitted. From these models, Sub-
hazard Ratios (SHR) and their respective 95% Confi-
dence Intervals (95% CI) were obtained. All models were
fitted separately for short-term (1 year) and medium-
term (5 years) follow-up, and were adjusted for all pa-
tient characteristics. The absence of interactions be-
tween explanatory variables and multi-collinearity was
verified. Absence of interactions was assessed using a
likelihood ratio test to compare the models including all
covariates and all second-grade possible interactions
with a model including all covariates without interac-
tions. As the results were non-significant, the absence of
significant interactions was assumed. Absence of multi-
collinearity was assessed looking at the correlation
matrix of the estimates from models and using variance
inflation factor tests (VIFs). All analyses were stratified
by joint, TKA and THA, and were carried out independ-
ently for comorbidity burden and for each comorbidity
in the Elixhauser index. The statistical significance level
was fixed at α = 0.05 and all analyses were done using
the statistical software Stata v.14.
Results
Patient characteristics and comorbidity distribution in the
study population
All patients undergoing TKA (posterior cruciate retain-
ing and posterior stabilized) and THA (conventional, ex-
cluding those with metal-on-metal bearing surface n =
173, 0.9%) caused by osteoarthritis (OA) and recorded in
the RACat from 01/01/2005 to 31/12/2016 were in-
cluded in the study population (TKA n = 49,993; THA
n = 18,070) (Fig. 1). Patients with emergency indetermin-
able hospital admission (TKA n = 105, < 0.2%; THA n =
85, 0.5%) or for whom the type of hospital in which they
were operated on was unknown (TKA n = 187, 0.4%;
THA n = 62, 0.3%) were excluded from the study, thus
yielding a total of 49,701 TKA and 17,923 THA proce-
dures included for analysis. The total number of deaths
was 3242 (6.5%) for TKA, and 1372 (7.7%) for THA.
Table 1 shows the general characteristics of the study
population separately for TKA (n = 49,701) and for THA
(n = 17,923). The most frequent characteristics for TKA
and THA, respectively, are: female (TKA 70.9% and
THA 50.6%), between 65 and 74 years old (TKA 43.5%
and THA 34.6%), operated on between 2011 and 2013
(TKA 29.1% and THA 33.5%), having a prosthesis with
cemented fixation type in TKA (76.4%) and uncemented
in THA (68.0%) and operated on in a reference hospital
(TKA 42.9% and THA 45.1%). Table 2 shows the
Fig. 1 Selection of the study sample
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distribution of comorbidity burden and the specific co-
morbidities in the Elixhauser index and their frequencies
of revision during the study period (2005–2016). In
both joints, the most frequent specific comorbidities
were hypertension without complications (TKA 54.3%
THA 44.5%) and diabetes without complications
(TKA 15.9% THA 12.4%). The specific comorbidities
with the highest revision rates were liver diseases in
TKA (5.1%) and peripheral vascular disorders in THA
(4.2%). In TKA depression was the third most com-
mon comorbidity (9.5%) and the least common co-
morbidity was AIDS, present in only 4 patients (<
0.1%). In THA, the third most common comorbidity
was hypothyroidism (7.9%) and the least common,
peptic ulcer disease excluding bleeding, present in
only 8 patients (< 0.1%).
Influence of comorbidity on the risk of revision in TKA
Table 3 shows the results for TKA. Regarding the revi-
sion burden (Fig. 2), a higher incidence of revision was
observed when the number of comorbidities was high,
both at 1 and at 5 years’ follow-up, but the difference
was only significant at 1 year and for 2 or more co-
morbidities, using 0 comorbidities as the reference
category. With respect to specific comorbidities, after
adjusting for patient characteristics, only obesity
(SHR: 1.53; 95% CI: 1.17–1.99), deficiency anemia
(SHR: 1.92; 95% CI: 1.18–3.11) and liver diseases
(SHR: 2.50; 95% CI: 1.49–4.20) were related to an in-
crease in revision risk at 1 year follow-up. The risk of
revision at 5 years’ follow-up only remained significant
for liver diseases (SHR: 1.60 95% CI: 1.11–2.29). Of
the other comorbidities that compose the Elixhauser
index, only the presence of paralysis was related with
an increased revision risk at 5 years (SHR: 3.14; 95%
CI: 1.49–6.60).
Influence of comorbidity on the risk of revision in THA
Looking at the incidence and risk of revision in THA
(Table 4), the burden of comorbidity (Fig. 3), especially
having 2 or more comorbidities, was shown to be signifi-
cantly related to a higher risk of revision, both at 1 year
Table 1 General characteristics of the study population by comorbidity burden (2005–2016)
TKA (n = 49,701) THA (n = 17,923)
n % n %
Sex
Men 14,455 29.1 8854 49.4
Women 35,246 70.9 9069 50.6
Year of the intervention
2005/2007 6883 13.9 2060 11.5
2008/2010 14,309 28.8 4939 27.6
2011/2013 14,457 29.1 6015 33.5
2014/2016 14,052 28.3 4909 27.4
Fixation type
Cemented 37,950 76.4 1596 8.9
Uncemented 353 0.7 12,186 68.0
Hybrid 7274 14.6 3895 21.7
Inverse hybrid 442 0.9 197 1.1
Not specified 3682 7.4 49 0.3
Type of hospital
High technology hospital 19,066 38.4 6416 35.8
Reference hospital 21,337 42.9 8089 45.1
Regional hospital 9298 18.7 3418 19.1
Median age in years (IQR) 73.0 (10.3) 71.4 (14.2)
Median follow-up in years (IQR) 4.7 (5.1) 4.6 (4.6)
Median number of comorbidities (IQR)a 1 (2) 1 (2)
TKA Total Knee Arthroplasty, THA Total Hip Arthroplasty
n: number of patients
%: percentage of patients
IQR Inter-quartile range
amin and max 0 and 7 respectively both for TKA and THA
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(SHR: 1.51; 95% CI: 1.05–2.15) and at 5 years’ follow-up
(SHR:1.32; 95% CI: 1.03–1.71). When focusing on the
most frequent specific conditions in the Elixhauser
index, only obesity was related to a higher revision risk,
both at 1 year (SHR: 1.81; 95% CI: 1.17–2.80) and at 5
years’ follow-up (SHR: 1.80 95% CI: 1.31–2.47). Periph-
eral vascular disorders were also related to an increase
in risk of revision at 5 years (SHR: 2.24; 95% CI: 1.06–
4.74). The presence of metastatic cancer (only at 1 year)
and the presence of psychosis (only at 5 years) might be
related to an increase in the risk of revision. These re-
sults might be spurious due to the small sample sizes
(n = 5 for metastatic cancer at 1 year and n = 17 for
psychosis at 5 years).
Table 2 Distribution of burden and specific comorbidities in the population from the Elixhauser index (2005–2016)
TKA (n = 49,701) THA (n = 17,923)
Primary Revision Primary Revision
n % n % n % n %
Burden of comorbidity
0 comorbidities 14,548 29.3 528 3.6 6862 38.3 175 2.5
1 comorbidity 17,479 35.2 585 3.3 6079 33.9 159 2.6
> =2 comorbidities 17,674 35.6 531 3.0 4982 27.8 130 2.6
Uncomplicated hypertension 26,968 54.3 837 3.1 7972 44.5 209 2.6
Uncomplicated diabetes 7903 15.9 221 2.8 2223 12.4 63 2.8
Obesity 5383 10.8 180 3.3 1235 6.9 46 3.7
Depression 4735 9.5 159 3.4 1160 6.5 33 2.8
Chronic pulmonary disease 4100 8.3 117 2.9 1420 7.9 33 2.3
Hypothyroidism 2928 5.9 93 3.2 746 4.2 16 2.1
Deficiency anemia 1162 2.3 34 2.9 471 2.7 12 2.5
Renal failure 964 1.9 18 1.9 391 2.2 7 1.8
Hypertension with complications 949 1.9 18 1.9 305 1.7 2 0.6
Valvular disease 886 1.8 22 2.5 300 1.7 2 0.7
Rheumatoid arthritis /collagen vascular disease 680 1.4 19 2.8 288 1.6 7 2.4
Other neurological disorders 724 1.5 22 3.0 233 1.3 5 2.1
Liver disease 673 1.4 34 5.1 284 1.6 8 2.8
Congestive heart failure 489 1.0 8 1.6 158 0.9 2 1.2
Peripheral vascular disorders 368 0.7 11 3.0 166 0.9 7 4.2
Solid tumor 226 0.5 3 1.3 100 0.6 2 2.0
Diabetes with complications 227 0.5 13 5.7 64 0.4 NR NR
Coagulopathy 221 0.4 3 1.4 77 0.4 NR NR
Blood loss anemia 215 0.4 13 6.1 67 0.4 NR NR
Fluid and electrolyte disorders 214 0.4 5 2.3 126 0.7 2 1.6
Alcohol abuse 194 0.4 6 3.1 132 0.7 3 2.2
Psychosis 172 0.4 3 1.7 77 0.4 5 6.5
Paralysis 88 0.2 7 8.0 39 0.2 2 5.1
Pulmonary circulation disorders 75 0.2 2 2.7 20 0.1 NR NR
Lymphoma 38 0.1 1 2.6 16 0.1 1 5.9
Peptic ulcer disease (excluding bleeding) 31 0.1 2 6.5 8 < 0.1 NR NR
Drug abuse 12 < 0.1 NR NR 28 0.2 NR NR
Metastatic cancer 10 < 0.1 NR NR 10 0.1 1 10.0
Weight loss 10 < 0.1 1 10.0 9 0.1 NR NR
AIDS 4 < 0.1 NR NR 16 0.1 1 5.9
THA Total Hip Arthroplasty, TKA Total Knee Arthroplasty
n: total number of patients in primary or revision THA or TKA during the study period (2005–2016)
%: percentage of patients
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Table 3 Cumulative incidence of revision at 1 and 5 years’ follow-up and effect of comorbidities from the Elixhauser index on the
risk of revision in Total Knee Arthroplasty (TKA)
1 year follow-up 5 years’ follow-up
np nr incidence
(95% CI)
SHR (95%CI) p value np nr incidence
(95% CI)
SHR (95% CI) p value
Burden of comorbidity 0.008 0.403
0 comorbidities 13,139 107 0.77 (0.63–0.92) 1.00 7532 333 3.74 (3.40–4.10) 1.00
1 comorbidity 15,838 142 0.84 (0.71–0.99) 1.18 (0.93–1.53) 8533 355 3.48 (3.18–3.79) 1.04 (0.92–1.19)
> =2 comorbidities 15,465 164 0.97 (0.83–1.13) 1.39 (1.09–1.78) 7505 321 3.47 (3.17–3.79) 1.06 (0.93–1.20)
Uncomplicated
hypertension
24,118 228 0.88 (0.77–1.00) 1.13 (0.93–1.37) 0.214 12,479 511 3.38 (3.14–3.63) 1.03 (0.93–1.15) 0.549
Uncomplicated
diabetes
7005 60 0.79 (0.61–1.01) 0.92 (0.70–1.21) 0.541 3556 139 3.17 (2.74–3.62) 0.91 (0.78–1.06) 0.216
Obesity 4649 66 1.29 (1.00–1.63) 1.53 (1.17–1.99) 0.002 2329 94 3.78 (3.22–4.40) 0.97 (0.82–1.14) 0.711
Depression 4171 39 0.87 (0.63–1.17) 1.08 (0.77–1.51) 0.651 1929 101 3.93 (3.30–4.61) 1.06 (0.89–1.27) 0.484
Chronic pulmonary
disease
3624 32 0.82 (0.57–1.14) 0.95 (0.66–1.36) 0.783 1795 76 3.25 (2.68–3.90) 1.01 (0.83–1.23) 0.933
Hypothyroidism 2524 24 0.85 (0.56–1.24) 1.12 (0.73–1.71) 0.603 1152 58 3.78 (3.02–4.67) 1.04 (0.83–1.30) 0.724
Deficiency anemia 990 17 1.58 (0.96–4.46) 1.92 (1.18–3.11) 0.008 457 15 3.34 (2.32–4.65) 1.09 (0.77–1.56) 0.615
Renal failure 775 9 1.02 (0.51–1.88) 1.25 (0.64–2.42) 0.515 262 9 2.40 (1.46–3.72) 0.98 (0.61–1.57) 0.938
Hypertension with
complications
758 9 1.03 (0.511.89) 1.35 (0.70–2.61) 0.376 256 8 2.38 (1.41–3.75) 0.94 (0.58–1.53) 0.815
Valvular disease 745 10 1.19 (0.61–2.11) 1.61 (0.85–3.03) 0.144 365 9 2.66 (1.64–4.07) 0.94 (0.60–1.49) 0.803
Rheumatoid arthritis 572 8 1.27 (0.60–2.39) 1.37 (0.68–2.78) 0.379 235 10 3.65 (2.20–5.65) 0.90 (0.57–1.44) 0.673
Other neurological
disorders
625 7 1.04 (0.47–2.06) 1.23 (0.58–2.59) 0.590 313 12 3.19 (1.98–4.85) 1.01 (0.64–1.60) 0.951
Liver disease 563 15 2.29 (1.34–3.66) 2.50 (1.49–4.20) 0.001 257 16 5.51 (3.81–7.66) 1.60 (1.11–2.29) 0.011
Congestive heart
failure
432 3 0.66 (0.18–1.80) 0.88 (0.28–2.74) 0.882 226 5 2.00 (0.94–3.78) 0.70 (0.35–1.39) 0.306
Peripheral vascular
disorders
338 4 1.11 (0.37–2.67) 1.35 (0.51–3.62) 0.545 198 7 3.62 (1.90–6.21) 1.16 (0.64–2.09) 0.626
Solid tumor 204 1 0.49 (0.05–2.50) 0.53 (0.08–3.79) 0.530 87 1 1.20 (0.23–3.97) 0.38 (0.10–1.57) 0.187
Diabetes with complications 191 2 0.97 (0.19–3.20) 1.08 (0.27–4.34) 0.911 78 8 5.71 (2.91–9.86) 1.82 (0.98–3.38) 0.057
Coagulopathy 190 2 0.93 (0.19–3.06) 1.10 (0.27–4.42) 0.896 85 1 1.46 (0.40–3.92) 0.53 (0.17–1.67) 0.280
Blood loss anemia 201 2 0.93 (0.19–3.07) 0.75 (0.19–3.12) 0.709 96 10 6.56 (3.56–10.80) 1.54 (0.87–2.77) 0.141
Fluid and electrolyte
disorders
184 1 0.50 (0.05–2.58) 0.57 (0.08–4.12) 0.575 62 4 2.73 (1.03–5.89) 0.91 (0.37–2.18) 0.841
Alcohol abuse 171 2 1.07 (0.21–3.52) 0.85 (0.21–3.48) 0.827 76 4 3.79 (1.54–7.69) 0.91 (0.37–2.23) 0.841
Psychosis 155 0 NR NC NC 54 3 2.49 (0.67–6.58) 0.60 (0.19–1.86) 0.378
Paralysis 79 2 2.36 (0.45–7.42) 2.67 (0.76–10.78) 0.169 31 5 11.79 (4.98–21.78) 3.14 (1.49–6.60) 0.003
Pulmonary circulation
disorders
58 1 1.41 (0.12–6.72) 1.87 (0.26–13.46) 0.533 27 1 3.09 (0.58–9.58) 1.05 (0.25–4.30) 0.951
Lymphoma 31 0 NR NC NC 12 1 3.49 (0.26–15.09) 1.16 (0.17–8.10) 0.881
Peptic ulcer disease 28 1 3.57 (0.26–15.41) 3.25 (0.45–23.51) 0.243 16 0 NR NC NC
Drug abuse 10 0 NR NC NC 3 0 NR NC NC
Metastatic cancer 9 0 NR NC NC 3 0 NR NC NC
Weight loss 8 0 NR NC NC 6 1 11.11 (0.6–38.77) 3.32 (0.46–23.81) 0.232
AIDS 4 0 NR NC NC 1 0 NR NC NC
np number of primary procedures at 1 and 5 years’ follow-up, nr number of revision procedures since the primary operation (from the beginning to 1
year and from 1 year to 5 years, at follow-up), SHR Subhazard ratio from competing risks models adjusted for sex, age, year of intervention, fixation type
and type of hospital, NR no revisions undergone from 1 to 5 years’ follow-up, NC Not calculable
Incidence (95%CI): cumulative incidence of revision considering patient death as a competing event and the 95% Confidence Interval
Variance inflation tests < 4 for all models
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Discussion
Our study suggests that the effect of comorbidity burden
on revision risk tends to be lower as time passes. In
terms of the specific comorbidities that compose the
Elixhauser index, the results obtained show that the in-
fluence of specific comorbidities on revision risk could
depend on the joint operated on. Additionally, while pa-
tients with obesity have a higher risk of revision in the
short-term, independent of the joint operated on, in the
medium-term this risk is higher only in THA patients.
These results could be helpful in interpreting the esti-
mates of the incidence of revision in TKA and THA in
the short-term, and they might also be relevant in en-
hancing clinical decision-making and patient consent.
As previous research has shown, comorbidity burden,
both in TKA and THA, might be related to the inci-
dence of revision in the short-term (1 year) but not in
the medium-term (5 years) [13]. These results are con-
gruent, at least partially, with ours and are likely related
to revision for postoperative infection. Other studies
have also illustrated that comorbidities, including obes-
ity, could affect the presence of postoperative infection
[25, 26], which usually occurs within the first year after
arthroplasty and can culminate in the need for early re-
vision. Therefore, future research using postoperative
complications as an outcome and considering comorbid-
ity as an explanatory factor could help clarify the influ-
ence of comorbidity on the risk of revision [25, 27, 28].
As previously pointed out in other reviews, both TKA
and THA outcomes might be worse in obese patients
than in non-obese [29–31] patients. These results are
consistent with ours in THA but not in TKA. Neverthe-
less, similar to previous research, we found that the
influence of obesity on the incidence of revision in pa-
tients undergoing TKA might be non-significant at the
medium-term [32, 33]. Therefore, this evidence allows
us to hypothesize that the influence of obesity on the in-
cidence of revision might be different over time depend-
ing, on the joint operated on. While obesity could have a
greater influence on the short-term incidence of revi-
sion, disappearing over time in TKA, this effect might be
higher over time in THA. Furthermore, since obesity
was taken from ICD codes, we were unable to stratify
for it, e.g. using the BMI cut-off values. However, given
that ICD codes are only identified if there is a specific
medical diagnosis, we can ensure that obesity could be
considered as a health problem on its own, in addition
to being a risk factor for other diseases. Further research
to test these hypotheses and taking other possibly related
factors, like physical activity, diet, or others into account,
might be useful in determining the specifics of the rela-
tionship between obesity and the risk of revision, par-
ticularly in TKA.
In terms of specific comorbidities, previous research
has suggested an association between preoperative
anemia and postoperative morbidity after TJA [34]. Add-
itionally, concerning liver diseases, as some studies have
shown, patients with these conditions could have a
higher likelihood of hospital readmission and prosthesis
revision, which corroborates our results [5, 35]. Still, it
seems that these pathologies could present a challenge
to the orthopedic field and steps should be taken to
thoroughly inform patients of increased risks for postop-
erative complications if they suffer from liver diseases or
preoperative anemia [36]. The results for paralysis are
contradictory to the results from previous studies, which
Fig. 2 Incidence of revision by burden of comorbidity in TKA
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Table 4 Cumulative incidence of revision at 1 and 5 years’ follow-up and effect of comorbidities from the Elixhauser index on the
risk of revision in Total Hip Arthroplasty (THA)
1 year follow-up 5 years’ follow-up
Np Nr Incidence
(95% CI)
SHR (95%CI) p value Np Nr incidence
(95% CI)
SHR (95% CI) P value
Burden of comorbidity 0.021 0.030
0 comorbidities 6270 61 0.92 (0.71–1.18) 1.00 3391 79 2.45 (2.06–2.88) 1.00
1 comorbidity 5501 70 1.17 (0.92–1.47) 1.29 (0.91–1.84) 2717 56 2.33 (1.95–2.77) 1.09 (0.85–1.40)
> =2 comorbidities 4388 68 1.39 (1.10–1.76) 1.51 (1.05–2.15) 1927 53 2.94 (2.44–3.50) 1.32 (1.03–1.71)
Uncomplicated
hypertension
7161 100 1.29 (1.06–1.56) 1.21 (0.91–1.62) 0.189 3448 78 2.60 (2.23–3.00) 1.12 (0.91–1.38) 0.276
Uncomplicated
diabetes
1949 31 1.43 (0.99–2.00) 1.30 (0.89–1.92) 0.177 901 24 2.91 (2.21–3.76) 1.25 (0.94–1.67) 0.130
Obesity 1072 23 1.90 (1.24–2.79) 1.81 (1.17–2.80) 0.007 479 21 4.39 (3.21–5.84) 1.80 (1.31–2.47) < 0.001
Depression 1030 15 1.32 (0.77–2.12) 1.16 (0.69–1.97) 0.575 455 16 3.35 (2.30–4.72) 1.28 (0.89–1.85) 0.185
Chronic pulmonary
disease
1270 20 1.42 (0.90–2.16) 1.32 (0.83–2.07) 0.240 564 11 2.52 (1.74–3.54) 1.07 (0.74–1.54) 0.729
Hypothyroidism 668 8 1.08 (0.51–2.05) 0.92 (0.45–1.90) 0.825 262 6 2.44 (1.36–4.05) 0.87 (0.51–1.50) 0.625
Deficiency anemia 421 6 1.28 (0.54–2.65) 1.14 (0.51–2.53) 0.752 187 6 2.91 (1.58–4.90) 1.26 (0.71–2.23) 0.421
Renal failure 323 4 1.04 (0.35–2.51) 0.85 (0.31–2.33) 0.753 100 2 1.84 (0.75–3.84) 0.84 (0.39–1.89) 0.667
Hypertension with complications 254 1 0.33 (0.03–1.72) 0.27 (0.04–1.94) 0.192 69 1 0.75 (1.50–2.51) 0.36 (0.09–1.45) 0.151
Valvular disease 259 2 0.69 (0.14–2.31) 0.55 (0.14–2.20) 0.399 113 0 NR NC NC
Rheumatoid arthritis 249 3 1.06 (0.30–2.87) 0.93 (0.30–2.90) 0.898 101 4 2.88 (1.27–5.62) 1.16 (0.55–2.45) 0.690
Other neurological
disorders
212 3 1.29 (0.36–3.49) 1.17 (0.38–3.67) 0.780 88 2 2.23 (0.84–4.85) 1.07 (0.44–2.59) 0.882
Liver disease 245 2 0.71 (0.14–2.38) 0.71 (0.18–2.87) 0. 630 106 5 3.42 (1.68–6.69) 1.23 (0.59–2.59) 0.581
Congestive heart
failure
131 2 1.36 (0.27–4.42) 1.10 (0.27–4.51) 0. 895 52 0 NR NC NC
Peripheral vascular
disorders
143 3 1.85 (0.51–4.93) 1.73 (0.54–5.40) 0. 349 67 4 5.39 (2.31–10.38) 2.24 (1.06–4.74) 0.034
Solid tumor 87 1 1.08 (0.09–5.25) 0.87 (0.12–6.13) 0. 885 40 1 2.20 (0.42–6.97) 1.01 (0.25–4.06) 0.987
Diabetes with
complications
55 0 NR NC NC 22 0 NR NC NC
Coagulopathy 71 0 NR NC NC 37 0 NR NC NC
Blood loss anemia 65 0 NR NC NC 39 0 NR NC NC
Fluid and electrolyte
disorders
113 1 0.80 (0.07–3.99) 0.68 (0.10–4.81) 0.701 47 1 1.67 (0.32–5.36) 0.77 (0.19–3.10) 0.715
Alcohol abuse 110 2 1.69 (0.33–5.42) 1.81 (0.47–7.23) 0.404 48 0 NR NC NC
Psychoses 65 2 2.72 (0.52–8.49) 2.62 (0.65–10.63) 0.176 17 2 5.88 (1.89–13.23) 2.77 (1.03–7.49) 0.044
Paralysis 35 1 2.63 (0.20–11.79) 2.46 (0.36–16.87) 0.375 14 1 5.58 (1.00–16.41) 2.55 (0.63–10.28) 0.188
Pulmonary circulation
disorders
17 0 NR NC NC 9 0 NR NC NC
Lymphoma 16 1 6.25 (0.41–24.69) 5.32 (0.75–37.33) 0.092 4 0 NR NC NC
Peptic ulcer disease 3 0 NR NC NC 3 0 NR NC NC
Drug abuse 23 0 NR NC NC 10 0 NR NC NC
Metastatic cancer 5 1 10.0 (0.57–35.81) 12.23 (1.46–102.46) 0.021 3 0 NR NC NC
Weight loss 6 0 NR NC NC 2 0 NR NC NC
AIDS 14 1 7,14 (0.45–27.52) 8.17 (0.82–56.81) 0.089 6 0 NR NC NC
np number of primary procedures at 1 and 5 years’ follow-up, nr number of revision procedures since the primary operation (from the beginning to 1
year and from 1 year to 5 years, at follow-up), SHR Subhazard ratio from competing risks models adjusted for sex, age, year of intervention, fixation type
and type of hospital, NR no revisions undergone from 1 to 5 years’ follow-up, NC Not calculable
Incidence (95%CI): cumulative incidence of revision considering patient death as a competing event and the 95% Confidence Interval
Variance inflation tests < 4 for all models
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might be due to differences within the paralysis cat-
egory itself [4, 37]. In the Elixhauser index, this cat-
egory could include conditions other than cerebral
palsy, which was the type of paralysis focused on.
Therefore, to carry out further studies on patients
with these conditions, it might be pertinent to have a
better understanding of the relationship between par-
alysis and the risk of revision in TKA.
In terms of the impact of specific conditions in THA,
peripheral arterial diseases were related to the risk of re-
vision at 5 years. Though our results are statistically sig-
nificant, other literature supporting this is lacking.
Furthermore, as shown in previous research, a greater
risk seems to be shown at 1 year revision than at 5 years
[38], which contradicts the findings of this study. Con-
cerning the lesser represented comorbidities, in THA
there is a slight possibility of a relationship between in-
creased risk of revision and metastatic cancer in the
short-term, and psychoses in the medium-term, which
has also been found in previous studies [13]. Regarding
patients with metastatic cancer and psychosis, it should
be noted that, due to the low number of patients in our
study with these comorbidities, despite being significant,
the relationships found could be spurious given the wide
Confidence Intervals found. These results, focused on
less common comorbidities, might serve as an explora-
tory analysis and starting point for further research.
Studies with larger sample sizes could solve the issue of
multiple testing with small sample sizes and might help
improve the knowledge of the relationship of these less
frequent pathologies and the risk of revision in THA. To
shed light on this relationship, it might be important for
patients and medical professionals to discuss and assess
possible consequences when considering a THA in a pa-
tient that suffers from metastatic cancer and psychoses
[20, 21, 39–41].
As limitations of this study, firstly, we should note that
in some specific comorbidities the sample size was ex-
tremely small and stratifying the analyses by the reasons
for revision was impossible. Despite this, it is important
to mention that the results from conditions with small
sample sizes, independent of the cause of revision, could
serve as a starting point to establish hypotheses for fur-
ther research including about the comorbidities related
to the different causes of revision. We should also men-
tion that some of the 95% CI found for less common
conditions are too wide to extract sound conclusions re-
garding their relationship with the risk of revision. Des-
pite this, these results might highlight potentially
relevant associations to be tested when larger sample
sizes are available. Another limitation that has to be
taken into account is the completeness of the RACat.
Though for primary procedures it could be considered
high, about 90%, the percentage of revision procedures
captured falls to about 70%. As the completeness in revi-
sion procedures is not as high as desired, this potentially
yields biased results and an underestimation of the im-
pact of comorbidity in revision rates. Furthermore, dif-
ferences in completeness between hospitals and over
time were also observed [23]. To combat the aforemen-
tioned limitations, the RACat became mandatory in
2017 and a retrospective search for information about
unreported revision procedures and hospitals with lower
completeness (identified through the MBD-HD) is con-
tinuously done within the RACat. As such, we expect an
increase in the completeness of the data in the
Fig. 3 Incidence of revision by burden of comorbidity in THA
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upcoming years, particularly for revision procedures and
the identified hospitals with lower completeness rates.
The retrospective search of unreported revisions, was
based on ICD-9-CM codes for hip and knee revision
procedures (00.70 to 00.87) but it should be done case
by case because the MBD-HD does not contain informa-
tion on laterality, which is essential to link the revision
with its corresponding primary procedure, at least in bi-
lateral arthroplasties.
It’s important to highlight that the levels of burden
were based on tertiles according to the distribution of
the Elixhauser index in our population, and not on the
severity of the comorbidities included in the index.
Therefore, we should mention that there were too few
studies to take the severity or weighting of the Elixhau-
ser index into account. Future studies to assign weights
to the comorbidities included in the index as well as
studies considering the severity of the diseases included
may help improve the knowledge of how comorbidity in-
fluences the incidence of revision of knee and hip
arthroplasties. Furthermore, specific combinations of co-
morbidities, like obesity (obtained from ICD codes and
not from height and weight) and diabetes without com-
plications, were not taken into account in this study. Be-
yond studying the burden of comorbidity and the
specific conditions in the Elixhauser index, considering
clusters of comorbidities could serve to better capture
the clinical complexity of patients undergoing THA and
TKA. However, it should be highlighted that our study
assumes a previous step necessary to learn which comor-
bidities are related to the risk of revision, which could
serve as a starting point for future research to investigate
which comorbidities could be related with each other as
well as with a combined risk of revision. Another limita-
tion is the possible increase in comorbidities over time.
While comorbidities are unlikely to change after 1 year,
they may change over 5 years [42]. Taking these po-
tential changes into account might be relevant in de-
termining the effects of comorbidity on the risk of
revision in THA and TKA. Lastly, it is important to
point out that only the risk of revision was taken into
account as an outcome in this investigation and that
findings from a specific geographical location, like
Catalonia, may not be transferable to other areas.
Furthermore, potential confounders like social
deprivation and some health-related habits were not
included because they are currently not within the
scope of the MBD-HD and RACat datasets. Future
collaborative registry studies including these potential
confounders and focusing on other outcomes like
mortality and PROMs would provide healthcare pro-
fessionals with more evidence for decision-making re-
garding best care options when faced with comorbid
patients needing a THA or TKA procedure.
Conclusion
In conclusion, our study shows that comorbidity burden
has significant effects on the risk of short-term revision
in both TKA and THA. These effects seem to be re-
duced over time after the primary arthroplasty proced-
ure, especially in the knee. Regarding specific
comorbidities from the Elixhauser index, obesity was
found to have a significant effect on the risk of short-
term revision in TKA and THA. In THA, this effect
seems particularly relevant and increases over time. Fur-
thermore, other specific comorbidities could be related
to revision risk, depending on the joint. Therefore, in-
cluding comorbidity burden and specific comorbidities
as an adjustment when analyzing the incidence of revi-
sion might be helpful in improving the precision of the
estimates in the short-term but not in the medium-term,
particularly in TKA. Further research with larger sample
sizes, longer follow-up periods and data from different
arthroplasty registries should be done to confirm these
results and explore the influence of the Elixhauser co-
morbidity index on other outcomes. This information
could be relevant for clinical decision-making, patient-
specific information and consent, and for improving the
results of both TKA and THA procedures.
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